Pharmacokinetic interactions between probenecid and the combination mycophenolate mofetil - cyclosporine/tacrolimus in stable renal allograft recipients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-000012-27-BE

Enrollment

Registered

2005-10-04

Start date

2005-09-06

Completion date

Unknown

Last updated

2025-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal transplant recipients treated with mycophenolate mofetil and tacrolimus.

Interventions

Trade Name: Probenecid Product Name: Probenecid Pharmaceutical Form: Capsule*

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: stable renal transplant recipients treated with mycophenolate mofetil and tacrolimus Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - use of other immunosuppressive drug therapy - use of durgs known to interact with rifampicin - combined organ transplants - documented non-compliance - acute rejection in the last 3 months - severely impaired renal function - hypoalbuminemia - liver disease - chronic diarrhea - pregnancy - fertile female patients of childbearing age

Design outcomes

Primary

Measure	Time frame
Main Objective: To demonstrate an interaction between mycophenolate mofetil and probenecid in renal allograft recipients;Secondary Objective: /;Primary end point(s): The observation of a significant influence of probenecid on mycophenolate mofetil pharmacokinetics	—

Countries

Belgium

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026